Phase 1 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 70 years old (any gender)
• People diagnosed with FLT3-positive acute myeloid leukemia (a specific type of blood cancer with a particular genetic marker)
• People whose doctors expect them to live for more than 3 months
• People with a physical functioning score of 0–2 on a standard medical scale (meaning able to carry out normal activity with at most moderate limitations)
• People whose leukemia has not responded to standard treatment, or has come back after treatment — specifically those who meet at least one of these situations:
  • After achieving remission, leukemia cells reappeared in the bone marrow, blood, or other areas of the body
  • People who had no response after 2 rounds of initial treatment
  • People whose leukemia came back within 12 months of achieving remission after intensive treatment
  • People whose leukemia came back after 12 months but did not respond to standard chemotherapy
  • People who have relapsed two or more times, or have leukemia present outside the bone marrow
• People whose kidney, heart, lung, liver, and blood clotting functions meet the specific levels required by the trial (the trial site will assess these through tests)
• People who have read and signed a consent form showing they understand the trial

Who may not be able to join:

• People who have had another type of cancer in the past 5 years (with some exceptions, such as certain fully treated skin cancers, cervical cancer in situ, localised prostate cancer, or breast ductal carcinoma in situ — confirm with trial site)
• People who have active hepatitis B, hepatitis C, HIV, cytomegalovirus (CMV), or syphilis infections, based on blood test results
• People with serious heart conditions, including unstable chest pain, a heart attack within the past 6 months, significant heart failure, or serious irregular heartbeat
• People with severe ongoing liver, kidney, or metabolic diseases that require medication
• People who have an active or uncontrolled infection requiring treatment within 7 days before joining the trial (minor urinary or upper respiratory infections may be exceptions — confirm with trial site)
• Women who are pregnant or breastfeeding, women planning a pregnancy within 2 years after treatment, or men whose partners are planning a pregnancy within 2 years after treatment
• People who have been taking steroid tablets or injections regularly within the 7 days before joining, or who are expected to need long-term steroids during the trial (steroid inhalers or creams are generally not included — confirm with trial site)
• People who have participated in another clinical trial within the past month
• People who show signs that the leukemia has spread to the brain or spinal fluid
• People who have graft-versus-host disease (a complication after some transplants) or who need medications that suppress the immune system
• People with a history of epilepsy or other conditions affecting the brain or nervous system
• People with a primary immune deficiency condition (a condition where the immune system does not work properly from birth)
• People whose doctors determine that collecting and preparing their cells for treatment is not suitable
• People considered unsuitable for other reasons, at the discretion of the medical team

Important: Always verify eligibility with the trial site directly before applying.